Skip to main content

East Bay drug maker to appeal FDA rejection of kidney treatment

The appeal, to be filed yeet this year, did little to change investors' minds on the fate of the drug — the stock gained just a penny on the day, then shed that penny in after-hours trading.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.